Sanofi’s experimental drug, tolebrutinib, has shown positive results in delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS). While the drug did not meet the primary endpoint in relapsing forms of MS, secondary data showed a significant delay in disability worsening. However, concerns regarding potential liver damage and effectiveness remain, impacting the drug’s revenue prospects.